Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 86.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $167.30 million which beat the analyst consensus estimate of $165.04 million by 1.37 percent. This is a 15.22 percent increase over sales of $145.20 million the same period last year.
Goldman, EQT In Talks To Buy Parexel For $9B: WSJ
Sweden’s EQT AB and Goldman Sachs Group Inc’s (NYSE:GS) investment arm are reportedly negotiating the acquisition of contract-research organization Parexel International Corp for nearly $9…
